Momenta Pharmaceuticals Inc. (MNTA): Today's Featured Health Care Winner
Momenta Pharmaceuticals Inc (MNTA) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1%. By the end of trading, Momenta Pharmaceuticals Inc rose 37 cents (2.5%) to $15.15 on average volume. Throughout the day, 998,219 shares of Momenta Pharmaceuticals Inc exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in a price between $14.73-$15.25 after having opened the day at $14.76 as compared to the previous trading day's close of $14.78. Other companies within the Health Care sector that increased today were: Cormedix Inc (CRMD), up 26.5%, Zoll Medical Corporation (ZOLL), up 22.9%, ProPhase Labs Inc (PRPH), up 20.3%, and IsoRay Inc (ISR), up 11%. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the characterization and process engineering of complex molecules. These complex molecules include proteins; polypeptides; and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). Momenta Pharmaceuticals Inc has a market cap of $766.1 million and is part of the drugs industry. The company has a P/E ratio of 3.4, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 1.3% year to date as of the close of trading on Wednesday. TheStreet Ratings rates Momenta as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and attractive valuation levels. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.
- You can view the full Momenta Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about MNTA
-
Momenta Pharmaceuticals (MNTA) Shares Cross Above 200 DMA
04:36PM 05/13/13
-
5 Names Seeing Bullish Options Flow
12:00PM 05/02/13
-
Oversold Conditions For Momenta Pharmaceuticals (MNTA)
12:39PM 04/30/13
-
Momenta Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For MNTA
12:30PM 04/22/13
-
TheStreet Ratings Top 10 Rating Changes
02:10PM 12/03/12
-
Momenta Pharmaceuticals' CEO To Present At Morgan Stanley Healthcare Conference (Transcript)
11:59AM 09/12/12
-
Momentas' CEO Discusses Q2 2012 Results - Earnings Call Transcript
05:03PM 08/02/12
Latest from TheStreet Wire
-
Randgold Resources Ltd (GOLD): Today's Featured Basic Materials Laggard
05:01PM 06/18/13
-
Pinnacle West Capital Corporation (PNW): Today's Featured Utilities Laggard
05:01PM 06/18/13
-
Saks Incorporated (SKS): Today's Featured Retail Laggard
05:01PM 06/18/13
-
Catamaran Corp (CTRX): Today's Featured Computer Software & Services Laggard
05:01PM 06/18/13
-
Leucadia National Corporation (LUK): Today's Featured Food & Beverage Laggard
05:01PM 06/18/13
-
Clearwire Corp (CLWR): Today's Featured Telecommunications Laggard
05:01PM 06/18/13
-
Infosys Ltd (INFY): Today's Featured Technology Laggard
05:01PM 06/18/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
